GenSci, an oral growth hormone, has been approved for clinical trials!
April 20, 2026
Source: drugdu
32
On April 16, the CDE website showed that GenSci Pharmaceutical's oral small molecule growth hormone secretion-promoting drug GS3-007a dry suspension has been approved for a new indication: the treatment of idiopathic short stature (ISS) in children. GS3-007a dry suspension is registered as a Class 1 chemical drug. It is an oral small molecule growth hormone secretin receptor type 1a (GHSR-1a) agonist. By acting on GHSR-1a of the pituitary gland, it enhances the release of endogenous growth hormone. It has been approved to conduct clinical trials for ISS, for the diagnosis of growth retardation in children caused by endogenous growth hormone deficiency and adult growth hormone deficiency.As one of the first oral growth hormone secretion-stimulating drugs to enter the clinical stage in China and the first in the world to be used for the treatment of ISS, the advancement of this drug has brought a new direction to the treatment of ISS and is expected to change the growth hormone injection treatment mode and usher in a new era of oral growth hormone.
https://mp.weixin.qq.com/s/hU1ze7rfy-20ZL5DkxHUnQ
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Hengrui’s new Class 1 drug for heart failure has been approved for clinical trials. April 20, 2026
- China’s innovative drugs’ breakthrough in the fight against cancer April 20, 2026
- Zai Lab’s “core” innovative drug, the first of its kind, is on the verge of market launch April 20, 2026
- Eli Lilly’s Tadalafil® and Tadalafil® (mijicillinumab) have been officially launched in China, opening a new chapter in precision targeted therapy for inflammatory bowel disease. April 20, 2026
- Why Did the “First Listed Company of China’s Biosimilars” Sell Its Only Innovative Drug for 450 Million? The Survival Rules for Biotechs Have Changed. April 17, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
